| ... |
Skip
navigation links
 | ... |
10th
Annual Symposium on Antiviral Drug Resistance: Targets and Mechanisms
The
10th Annual Symposium on Antiviral Drug Resistance: Targets and Mechanisms will
be held November 15-18, 2009, at the Wyndham Virginia Crossings Hotel and Conference
Center in Richmond, Virginia. Sponsored by the University of Pittsburgh and co-sponsored
by the HIV Drug Resistance Program, NCI, this annual meeting brings together researchers
in a variety of virus systems to exchange new information on viral targets for
therapy, on antiviral drugs, and on resistance to these drugs. The focus is on
specific molecular targets, their normal structure and function, their interactions
with antiviral drugs, and the evolutionary basis and specific mechanisms of viral
resistance. Organized by molecular target, the program includes presentations
by invited speakers as well as oral and poster presentations selected from submitted
abstracts. Details about the Symposium -- including online registration, abstract
submission, and participation support -- are available at the Symposium
website.
Dr.
Stuart Le Grice Invited to Co-Edit Special Issue of Current Topics in Medicinal
Chemistry Dr.
Stuart F.J. Le Grice (HIV Drug Resistance Program) has been invited
to co-edit, with Dr. A. Jun Komano (National Institute of Infectious Diseases,
Japan), a special issue of Current
Topics in Medicinal Chemistry dedicated to HIV therapy.
Dr.
Eric Freed Appointed as Editor-in-Chief of Viruses Dr.
Eric Freed has been appointed as the first Editor-in-Chief of Viruses,
a new open-access journal that provides an advanced forum for studies of viruses.
The journal's broad scope includes all classes of viruses, viral epidemiology,
virus-like agents, vaccines, and antiviral drugs.
Dr.
Vinay Pathak to Serve as Guest Editor for Special Issue of Viruses
Dr.
Vinay Pathak has been appointed as the Guest Editor for the HIV
Drug Resistance special issue of Viruses,
which will be published in October 2009.
[Top
of page]
|
Dr.
Stephen Oroszlan Honored for Research on HIV Protease
Dr. Stephen
Oroszlan, Scientist Emeritus, was honored at the Symposium on HIV Protease and
Beyond: The Past, Present, and Future of HIV Structural Biology, held at NCI-Frederick
in January 2009. Organized by the NCI Center of Excellence in HIV/AIDS & Cancer
Virology with support from the Center for Cancer Research and NIH Intramural AIDS
Targeted Antiretroviral Program, the Symposium commemorated the 20th anniversary
of the publication of the crystal structure of HIV protease, a turning point in
the utilization of structural information for drug design. The relationship between
structural biology and drug design for other HIV targets was also highlighted
at the Symposium.
 In
the opening session, Dr. Michael Gottesman (NIH Deputy Director for Intramural
Research) presented an award to Dr. Oroszlan in recognition of his many contributions
to our understanding of the structure of retroviruses, and for his seminal work
on viral proteases. Dr. Oroszlan gave the opening keynote talk, describing the
key events in retroviral protease research and the discovery of HIV protease.
He has been awarded three U.S. patents and one European patent on HIV protease.
His numerous honors include the award of a Doctor Honoris Causa Degree from the
University of Debrecen Medical School in 1993, election to the Hungarian Academy
of Sciences as a Foreign Associate in 1994, a Retroviral Retrospective Symposium
to Honor Dr. Stephen Oroszlan held at Hood College in 1994, and the Mór Kaposi
Research Foundation Award in 2000.
[Top
of page]
| Study
on HIV-1 Trafficking Selected as Top CCR Advance in HIV/AIDS for 2008
A
study by Dr.
Eric Freed and colleagues on "Real-Time Visualization of HIV-1 Gag
Trafficking in Infected Macrophages" was selected as the Center for Cancer Research
(CCR) Science Advance of the year in HIV/AIDS research. Featured in a recent CCR
In the Journals article, Dr. Freed's study "demonstrates that HIV-1 particles
are retained in internal reservoirs within host cells from which they can be rapidly
released at opportune times, such as when contact is established with uninfected
cells....The results of this study may set the groundwork for the development
of new HIV treatments based on interruption of intracellular viral trafficking."
Further details, including the original publication of the study in PLoS Pathogens,
are available at the Recent
HIV DRP Publications web page.
[Top
of page]
HIV
Drug Resistance Program Hosts Visitors Observing BL2*/BL3 Work
| 
Dr.
Nancy Chung (second from right) in the BL2* staging area with (from left to right)
Margaret Lange, Eleftherios Michailidis, and Bruno Marchand.
|
The
HIV Drug Resistance Program hosted several members of the laboratories of Drs.
Donald Burke and Stefan Sarafianos from the University of Missouri to demonstrate
the BL2*/BL3 practices and protocols used in the DRP. Dr. Nancy Chung in Dr.
Vineet KewalRamani's group conducted the training for the visitors,
which included Dr. Burke and fellows Margaret Lange, Bruno Marchand, and Eleftherios
Michailidis. In addition to demonstrating experiments using GHOST cell infections
with live HIV-1, Dr. Chung demonstrated TZM cell titrations, which are commonly
used by laboratories conducting research on antiviral inhibitors. Observing the
BL2*/BL3 work firsthand proved very helpful to the guests; in Dr. Burke's words,
"there were a thousand little details that can only be learned by watching it
in action."
| [Top
of page] |
News
Articles and Press Releases
News Articles on Recent Nature Paper by Le Grice Lab The
following news articles highlight a Nature paper published in May 2008 by a collaborative
team including members of the Le Grice lab (Drs.
Stuart Le Grice and Jason
Rausch) on their findings that the enzymatic activities of HIV reverse
transcriptase are determined by its binding orientation on the substrate (to view
the articles, click on the titles below):
Nature
News and Views feature:
Molecular Biology: An HIV Secret Uncovered (PDF
- 451KB)
Harvard
University Gazette Online feature:
Research Reveals Workings of Anti-HIV
Drugs
CCR
Connections feature:
Reverse Transcriptase: When Function Follows Direction
The
original article by Abbondanzieri et al. describing the study (Nature 453: 184-189):
Dynamic binding orientations direct activity of HIV reverse transcriptase (PDF
- 546KB)
News Articles on Recent PNAS Paper by Host-Virus Interaction Branch
The
following news articles highlight a PNAS paper published in March 2008 by a collaborative
team including members of the Host-Virus Interaction Branch (Sarah Palmer, Frank
Maldarelli, Ann Wiegand, John
Coffin, John
Mellors) on the persistence of low-level viremia for at least 7 years
in HIV-infected patients on potent antiretroviral therapy (to view the articles,
click on the titles below):
U.S.
News & World Report:
HIV Can Hide in Cells for Years
BBC
News:
HIV 'hides from drugs for years'
Forbes:
HIV Can Hide in Cells for Years
HealthAtoZ.com:
HIV Can Hide in Cells for Years
The
original article by Palmer et al. describing the study (Proc. Natl. Acad. Sci.
USA 105: 3879-3884, 2008):
Low-level viremia persists for at least 7
years in patients on suppressive antiretroviral therapy (PDF - 664KB)
Center for Cancer Research "In the Journals" Feature on Recent PNAS
Article by Freed Lab The
following article on the Center for Cancer Research website highlights a May 2007
PNAS paper by Drs.
Eric Freed and Abdul
Waheed and their collaborators on a novel mechanism by which HIV
circumvents the antiviral activity of amphotericin B methyl ester (AME):
HIV
and Drug Resistance: Hitting a Moving Target (PDF - 214KB)
The
original article by Waheed et al. describing the study (Proc. Natl. Acad. Sci.
USA 104: 8467-8471, 2007):
HIV-1 escape from the entry-inhibiting effects
of a cholesterol-binding compound via cleavage of gp41 by the viral protease (PDF
- 675KB)
Frederick News-Post Article on Student Intern Bilguujin Dorjsuren
The
following front-page article features Bilguujin Dorjsuren, a student intern in
the laboratory of Dr.
David Derse (reprinted with permission of the Frederick News-Post
and Randall Family, LLC as published on May 16, 2007):
She
speaks four languages, interns at NCI — and she’s only 18
Press Releases and Related Articles on Bevirimat (PA-457), a Novel
HIV-1 Inhibitor The
following articles announce the results of clinical trials on bevirimat (PA-157),
the first-in-class HIV-1 maturation inhibitor developed by Panacos Pharmaceuticals
in collaboration with a research
team in the HIV Drug Resistance Program, National Cancer Institute
(to view the articles, click on the titles below):
May
2007 Press Release from Panacos Pharmaceuticals:
Preclinical Study Finds
Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance
to Panacos' Bevirimat
August
2006 Article in the Boston Globe:
Chinese Herb May Yield Drug for AIDS
June
2006 Press Release from Panacos Pharmaceuticals:
Panacos Presents Data
on Lack of Clinical Resistance Development to Bevirimat (PA-457) at International
HIV Drug Resistance Conference
June
2006 Article in Scientific American:
A New Assault on HIV: The Constant
Search for Weak Points in the Virus Yields Ideas for a Wholly New Class of Drug
April
2006 Press Release from Panacos Pharmaceuticals:
PA-457 Phase 2b Trial
Design Agreed with FDA; Study Projected to Begin in Q2 2006
August
2005 Press Release from Panacos Pharmaceuticals:
Panacos Drug Candidate
PA-457 Shows Potent Antiviral Activity in HIV-infected Patients; Viral Load Reduction
Meets Primary Endpoint of Phase 2a Study
May
2005 Press Release from Panacos Pharmaceuticals:
V. I. Technologies and
Collaborators Present Three Studies on the Molecular Target of PA-457, First-in-Class
HIV Maturation Inhibitor, at the Cold Spring Harbor Retrovirus Conference
BusinessWeek
online:
A Better Way To Ambush AIDS?—Panacos Pharmaceuticals' experimental
drug opens the door to a new line of attack
To view the
published results of a study elucidating the mechanism of action of PA-457, go
to Proc.
Natl. Acad. Sci. USA 100: 13555-13560, 2003 (PDF - 384KB).
Press Release and Related Articles on the Discovery of How One Type
of Cancer-Causing Virus Evades the Body's Natural Defenses The
following articles describe research performed by Dr.
David Derse and colleagues on the mechanism by which human T-cell
leukemia virus type 1 circumvents the body's natural defenses (to view the articles,
click on the titles below):
February
2007 Press Release from the National Cancer Institute:
NCI Scientists
Discover How T-Cell Leukemia Viruses Evade Body's Defense Mechanisms
Cancer
Research Highlights Article in the NCI Cancer Bulletin (page 3):
Study
Describes How Virus Evades Body's Defenses (PDF - 434KB)
Featured
Article in NIH Research Matters:
How T-Cell Leukemia Viruses Virus Evade
the Body's Defenses
The
original article by Derse et al. describing the study (Proc. Natl. Acad. Sci.
USA 104: 2915-2920, 2007):
Resistance of human T cell leukemia virus
type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid (PDF -
692KB)
Popular Mechanics Feature and Related Article on the RT-SHIV Animal
Model of HIV Infection The
following articles describe research performed by Drs.
Vineet KewalRamani and Zandrea
Ambrose on the RT-SHIV animal model of HIV-1 pathogenesis, persistence,
and response to antiretroviral therapy (to view the articles, click on the titles
below):
December
2006 PopularMechanics.com World AIDS Day special on the RT-SHIV research in Dr.
KewalRamani's lab:
Fighting HIV by Building a New Killer
The
original article by Ambrose et al. describing the RT-SHIV model (J. Virol. 78:
13553-13561, 2004):
In vitro characterization of a simian immunodeficiency
virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse
transcriptase to study antiviral resistance in pigtail macaques (PDF - 207KB)
NCI-Frederick
Spotlight on Dr. John Coffin This
interview with Dr.
John Coffin was the featured article in August 2005 on the home page
of the NCI-Frederick
website.
NCI-Frederick
Spotlight on Dr. Stephen Hughes This
interview with Dr.
Stephen Hughes was the featured article in July 2004 on the home
page of the NCI-Frederick
website.
in-cites
-- An Interview with Dr. John M. Coffin In
this December 2003 in-cites
interview, Dr.
Coffin discusses his highly cited Science paper, "HIV population
dynamics in vivo—implications for genetic variation, pathogenesis, and therapy."
|
[Top
of page]
|
NCI
Center of Excellence in HIV/AIDS & Cancer Virology
The
Center of Excellence in HIV/AIDS and Cancer Virology (CEHCV) was formed in 2006
within the Center for Cancer Research, NCI. The mission of the CEHCV is to facilitate
and rapidly communicate advances in the discovery, development, and delivery of
antiviral and immunologic approaches for the prevention and treatment of HIV infection,
AIDS-related malignancies, and cancer-associated viral diseases. Drs.
Stuart Le Grice, a Principal Investigator in the HIV Drug Resistance
Program, was appointed Head of the CEHCV. Further details are available at the
Center's website. |
[Top
of page]
|
Think
Tank Meeting
|
The HIV Drug
Resistance Program (DRP) hosted the 2008 Think Tank Meeting on April 16 at the
NCI-Frederick Conference Center. Covering all topics related to retrovirology,
this annual event brings together investigators from NCI, NIH, and academic institutions
in the Washington and Baltimore areas with research interests related to the Program's
goals for a stimulating day of short presentations and discussion. Since its inception
in 1998, the Think Tank Meeting has been very successful at fostering collaborations
among these investigators.
 The
DRP has broadened participation in the Think Tank Meeting by periodically inviting
senior graduate students involved in retrovirus research outside the NIH to attend
the Think Tank and to participate in an informal symposium with members of the
DRP the following day (see Invited
Student Symposium below).
2008
Think Tank Presentations: |
Yossef Raviv |
ATP synthase beta chain is a receptor for HIV-1 transmission by DC-SIGN expressing
Raji cells
|
David Derse |
Quantitative comparison of HIV-1 and HTLV-1 cell-to-cell infection in a model
cell culture system
|
Maribeth Eiden |
Gibbon ape leukemia virus: An emerging zoonosis
|
Sher Hendrickson |
Mitochondrial DNA haplogroups influence AIDS progression
|
Kyeongeun Lee |
HIV-1 PR kills cycling cells
|
Mary Kearney |
HIV-1 evolution in vivo
|
Wei Zao Chen |
Human domain antibodies against HIV-1 as exceptionally potent cross-reactive neutralizers
|
Jacob Estes |
Early host innate immune response at the portal of entry following intra-vaginal
transmission
|
Frank Maldarelli |
Persistent HIV-1 viremia during suppressive antiviral therapy
|
Shixing Tang |
Nanoparticle based new assays for enhanced detection of HIV and other pathogens
|
Andrew Yang |
Small molecule screening for reactivation of latent HIV
|
Antonio Valentin |
Electroporation of optimized DNA vaccines leads to greatly enhanced responses
in blood and mucosal surfaces
|
James Thomas |
Possible mechanism of premature reverse transcription in NC-mutant HIV-1
|
Stuart Le Grice |
Interaction of RNase H inhibitors with RT
|
Christie Vu |
Evaluation of nucleoside analogs against HIV-1 reverse transcriptase
|
Krista Frankenberry |
HIV-1 RT connection domain mutations decrease RNase H cleavage and increase AZT
resistance
|
Min Li |
Synapsis of viral DNA ends by HIV-1 integrase
|
Atreyi Chatterjee |
The chromodomain of Tf1 integrase is critical for integration and target site
selection
|
Jessica Marinello |
HIV-1 integrase mutations and resistance to Raltegravir and Elvitegravir
|
Eri Miyagi |
Replication of Vif-deficient HIV-1 in a semi-permissive APOBEC3G expressing T
cell line
|
Xiao-Fang Yu |
A critical region in potent anti-viral cytidine deaminases mediates specific RNA
binding and HIV-1 inhibition
|
Anjali Joshi |
Functional replacement of a retroviral late domain by ubiquitin fusion
|
David Ott |
Assembly properties of a nucleocapsid deletion mutant
|
Rachael Crist |
Assembly properties of Gag-zipper chimeric proteins
|
Michael Moore |
Match.com: The most popular "cyt" for HIV-1 gRNA to find its partner
|
[Top
of page]
|
Invited
Student Symposium
 In
conjunction with the 2005 Think Tank Meeting, the DRP hosted the third Invited
Student Symposium on April 6. After attending the Think Tank Meeting, the following
senior graduate students from outside the NIH community presented short talks
on their retrovirology research to the DRP staff and convened with the Program's
faculty for informal discussions.
Danso Ako-Adjei
(Volker Vogt Laboratory, Cornell University)
Jared
Auclair
(Celia Schiffer Laboratory, University of Massachusetts Medical School)
Shardell Hawkins
(Michael Summers Laboratory, Howard Hughes Medical
Institute and University of Maryland Baltimore County)
Shari Kaiser
(Michael Emerman Laboratory, Fred Hutchinson Cancer Research Center)
Juliana Leung
(Stephen Goff Laboratory, Howard Hughes Medical Institute
and Columbia University College of Physicians and Surgeons)
Urvi Parikh
(John Mellors Laboratory, University of Pittsburgh School of Medicine)
David Sayah
(Jeremy Luban Laboratory, Columbia University College of Physicians
and Surgeons)
| [Top
of page]
Dr.
Eric Freed Appointed as Guest Editor for Special Issue of Virus Research
|
|
The cover image
was reprinted from Virus
Research, Vol. 106, No. 2, Copyright 2004, with permission from
Elsevier. The original source of the artwork was Proc. Natl. Acad. Sci. USA
99: 955-960, 2002 (Copyright 2002, National Academy of Sciences, U.S.A.).
|
Dr.
Eric Freed served as Guest Editor for the December 2004 issue of
Virus
Research, which was devoted to mechanisms of enveloped virus
budding. In addition to writing the preface
(PDF - 33KB) to this special issue, Dr. Freed solicited chapters
from leading investigators studying a range of enveloped viruses, edited the chapters,
and coordinated the review process. He also contributed a chapter on retrovirus
budding (Demirov
and Freed, pp. 87-102, PDF - 443KB) and provided the artwork for
the journal's cover,
showing an electron micrograph of TSG-5' inhibiting HIV-1 budding.
|
[Top
of page]
Last
modified: 25 June 2009 | ... |
